One-alpha

One-alpha

A brand name for ALFACALCIDOL.
References in periodicals archive ?
announced today that it has filed a New Drug Submission with the Canadian Health Protection Branch for the oral formulation of one-alpha D2 for the treatment of secondary hyperparathyroidism associated with end-stage renal disease.
DRAXIS holds the Canadian rights to one-alpha D2 from Bone Care International, Inc.
Food and Drug Administration (FDA) for an intravenous formulation of one-alpha D2.
For the past year, Bone Care has been conducting clinical trials in patients with prostate cancer using one-alpha D2, a vitamin D analog.
NASDAQ:BCII) today announced the final results from two multicenter Phase 3 clinical trials of oral One-alpha D2, its lead product.
medical centers, to examine the efficacy and safety of oral One-alpha D2 as a new treatment for secondary hyperparathyroidism associated with end-stage renal disease.
Bone Care has completed Phase 3 development of oral One-alpha D2 as a treatment for secondary hyperparathyroidism associated with end stage renal disease.
NASDAQ:BCII) today announced publication of results from a multicenter Phase 2 clinical trial with one-alpha D2 in the January issue of Kidney International (Vol.
Bone Care has completed its enrollment of patients into a Phase 3 clinical trial on its lead drug, one-alpha D2 in the U.
It also is developing one-alpha D2 and other proprietary compounds for indications including osteoporosis, primary hyperparathyroidism, psoriasis, prostate cancer and breast cancer.
to confirm the efficacy and safety of its lead drug, one-alpha D2, as a treatment for secondary hyperparathyroidism associated with renal disease.